Development and validation of probe drug cocktails for the characterization of CYP450-mediated metabolism by human heart microsomes

References

• Chen C-D, Doray B, Kemper B. (1997). Efficient assembly of functional cytochrome P450 2C2 requires a spacer sequence between the N-terminal signal anchor and catalytic domains. J Biol Chem 272:22891–7.
   PubMed Web of Science ®Google Scholar
• Cornish-Bowden A. (1974). A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors (Short Communication). Biochem J 137:143–4.
   PubMed Web of Science ®Google Scholar
• Cornish-Bowden A. (1986). Why is uncompetitive inhibition so rare? A possible explanation, with implications for the design of drugs and pesticides. FEBS Lett 203:3–6.
   PubMed Web of Science ®Google Scholar
• Delozier TC, Kissling GE, Coulter SJ, et al. (2007). Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos 35:682–8.
   PubMed Web of Science ®Google Scholar
• Denisov IG, Makris TM, Sligar SG, Schlichting I. (2005). Structure and chemistry of cytochrome P450. Chem Rev 105:2253–77.
   PubMed Web of Science ®Google Scholar
• Easterbrook J, Lu C, Sakai Y, Li AP. (2001). Effects of organic solvents on the activities of cytochrome P450 Isoforms, UDP-dependent glucuronyl transferase, and phenol sulfotransferase in human hepatocytes. Drug Metab Dispos 29:141–4.
   PubMed Web of Science ®Google Scholar
• Elbekai RH, El-Kadi AO. (2006). Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther 112:564–87.
   PubMed Web of Science ®Google Scholar
• Engtrakul JJ, Foti RS, Strelevitz TJ, Fisher MB. (2005). Altered AZT (3′-azido-3'-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos 33:1621–7.
   PubMed Web of Science ®Google Scholar
• Fuhr U, Jetter A, Kirchheiner J. (2007). Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach. Clin Pharmacol Ther 81:270–83.
   PubMed Web of Science ®Google Scholar
• Guengerich FP. (2008). Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70–83.
   PubMed Web of Science ®Google Scholar
• Hashizume T, Imaoka S, Mise M, et al. (2002). Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol Exp Ther 300:298–304.
   PubMed Web of Science ®Google Scholar
• Johnston JB, Ouellet H, Podust LM, Ortiz De Montellano PR. (2011). Structural control of cytochrome P450-catalyzed ω-hydroxylation. Arch Biochem Biophys 507:86–94.
   PubMed Web of Science ®Google Scholar
• Krishna D, Klotz U. (1994). Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26:144–60.
   PubMed Web of Science ®Google Scholar
• Kudo T, Ozaki Y, Kusano T, et al. (2016). Effect of buffer conditions on CYP2C8-mediated paclitaxel 6α-hydroxylation and CYP3A4-mediated triazolam α- and 4-hydroxylation by human liver microsomes. Xenobiotica 46:241–6.
   PubMed Web of Science ®Google Scholar
• Lee CA, Neul D, Clouser-Roche A, et al. (2010). Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38:347–56.
   PubMed Web of Science ®Google Scholar
• Liu K-H, Kim M-G, Lee D-J, et al. (2006). Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos 34:1793–7.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hirama T, Matsubara T, et al. (2002). Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 30:1240–5.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Yamazoe Y. (2001). Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol 51:133–42.
   PubMed Web of Science ®Google Scholar
• Michaud V, Frappier M, Dumas M-C, Turgeon J. (2010). Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. PLoS One 5:e15666.
   PubMed Web of Science ®Google Scholar
• Michaud V, Simard C, Turgeon J. (2007). An improved HPLC assay with fluorescence detection for the determination of domperidone and three major metabolites for application to in vitro drug metabolism studies. J Chromatogr B 852:611–16.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Morganroth J. (1999). Cardiac effects of ebastine and other antihistamines in humans. Drug Saf 21 Suppl 1:69–80. discussion 81–7.
   PubMed Web of Science ®Google Scholar
• Motulsky H. 1995. Intuitive biostatistics. 1st ed. New York: Oxford University Press.
   Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. (2006). How many drug targets are there? Nat Rev Drug Discov 5:993.
   PubMed Web of Science ®Google Scholar
• Preissner SC, Hoffmann MF, Preissner R, et al. (2013). Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS One 8:e82562.
   PubMed Web of Science ®Google Scholar
• Segel IH. (1993). Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. New York: Wiley Classics Library.
   Google Scholar
• Spaggiari D, Geiser L, Daali Y, Rudaz S. (2014). A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies. J Pharm Biomed Anal 101:221–37.
   PubMed Web of Science ®Google Scholar
• Thelen K, Dressman JB. (2009). Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61:541–58.
   PubMed Web of Science ®Google Scholar
• Thum T, Borlak J. (2000). Gene expression in distinct regions of the heart. Lancet 355:979–83.
   PubMed Web of Science ®Google Scholar
• Thum T, Borlak J. (2002). Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J 16:1537–49.
   PubMed Web of Science ®Google Scholar
• Whiteley CG. (2000). Enzyme kinetics: partial and complete uncompetitive inhibition. Biochem Educ 28:144–7.
   PubMedGoogle Scholar
• Wu S, Moomaw CR, Tomer KB, et al. (1996). Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460–8.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Shimada N. (1999). Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes. Xenobiotica 29:231–41.
   PubMed Web of Science ®Google Scholar
• Yoshino M, Murakami K. (2009). A graphical method for determining inhibition constants. J Enzyme Inhibit Med Chem 24:1288–90.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–41.
   PubMed Web of Science ®Google Scholar